Glaxo CEO Says Pfizer Joint Venture to Strengthen Pharma Pipeline

The transcript discusses GSK's strategic moves, including a joint venture with Pfizer to strengthen its pharma and vaccines business while creating a new consumer healthcare leader. The strategy involves separating the businesses to focus on growth and shareholder value. GSK plans to invest in its pharma pipeline through acquisitions and digital capabilities. The impact of Brexit on GSK's operations is also addressed, with a focus on ensuring supply security and maintaining a global presence.

What role does digital capability play in GSK's strategy moving forward?

How does GSK plan to manage the uncertainties related to Brexit?

What are the expected outcomes of separating the consumer healthcare business from the pharmaceuticals business?